热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　交银国际发布研究报告称，下调康宁杰瑞制药-B（09966）目标价至5港元，维持“中性”评级。公司产品销售短期承压，HER2渠道多项资产研发快速推进。该行预计KN026和JSKN003有望在国内合计产生近50亿元的峰值销售额。

　　该行表示，上调康宁杰瑞制药2024年收入预测至6.57亿元人民币（下同），以反映JSKN003授权合作的相关首付款，但考虑到行业合规整治影响恩维达销售、个别在研药物上市节奏推迟，下调2025年收入预测至4.5亿元，并下调恩维达和KN046的经POS调整销售峰值至11亿及5亿元。同时，该行大幅下调2024-25年研发和销售费用预测。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.